Cover Image

Aposense Ltd.:產品平台分析

Aposense Ltd. - Product Pipeline Review - 2015

出版商 Global Markets Direct 商品編碼 318946
出版日期 內容資訊 英文 19 Pages
Back to Top
Aposense Ltd.:產品平台分析 Aposense Ltd. - Product Pipeline Review - 2015
出版日期: 2015年08月12日 內容資訊: 英文 19 Pages



Aposense Ltd. 是開發小分子治療藥的醫藥品廠商。該公司的產品有胰臟癌治療藥和帕金森氏症治療的前驅藥物左旋多巴等。此外也製造用於治療大腸癌,肺癌,卵巢癌類轉移性實體腫瘤的化合物。

本報告提供Aposense Ltd.的治療藥開發平台現狀及各開發階段比較分析,提供您藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,最新的企業新聞和發表,後期階段及中止的計劃等相關資訊。

Aposense Ltd.的基本資料

  • Aposense Ltd.概要
  • 主要資訊
  • 企業資料

Aposense Ltd.:R&D概要

  • 主要的治療範圍

Aposense Ltd.:開發平台的評估

  • 各開發階段的開發中產品
  • 單劑產品

Aposense Ltd.:開發中產品概況

  • 初期階段的開發中產品
    • 前臨床階段的產品/聯合治療模式

Aposense Ltd.:藥物簡介

  • ATT-11T
  • ATT-Gem
  • ATT-LD

Aposense Ltd.:開發平台分析

  • 標的別
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

Aposense Ltd.:總公司和子公司的所在地



Product Code: GMDHC07511CDB


Global Markets Direct's, 'Aposense Ltd. - Product Pipeline Review - 2015', provides an overview of the Aposense Ltd.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Aposense Ltd.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


  • The report provides brief overview of Aposense Ltd. including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Aposense Ltd.'s human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Aposense Ltd.'s pipeline products

Reasons to buy

  • Evaluate Aposense Ltd.'s strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Aposense Ltd. in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Aposense Ltd.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Aposense Ltd. and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Aposense Ltd.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Aposense Ltd. and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Aposense Ltd. Snapshot
    • Aposense Ltd. Overview
    • Key Information
    • Key Facts
  • Aposense Ltd. - Research and Development Overview
    • Key Therapeutic Areas
  • Aposense Ltd. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • Aposense Ltd. - Pipeline Products Glance
    • Aposense Ltd. - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
  • Aposense Ltd. - Drug Profiles
    • ATT-11T
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ATT-Gem
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ATT-LD
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Aposense Ltd. - Pipeline Analysis
  • Aposense Ltd. - Pipeline Products by Target
  • Aposense Ltd. - Pipeline Products by Route of Administration
  • Aposense Ltd. - Pipeline Products by Molecule Type
  • Aposense Ltd. - Pipeline Products by Mechanism of Action
  • Aposense Ltd. - Locations And Subsidiaries
    • Head Office
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Aposense Ltd., Key Information
  • Aposense Ltd., Key Facts
  • Aposense Ltd. - Pipeline by Indication, 2015
  • Aposense Ltd. - Pipeline by Stage of Development, 2015
  • Aposense Ltd. - Monotherapy Products in Pipeline, 2015
  • Aposense Ltd. - Preclinical, 2015
  • Aposense Ltd. - Pipeline by Target, 2015
  • Aposense Ltd. - Pipeline by Route of Administration, 2015
  • Aposense Ltd. - Pipeline by Molecule Type, 2015
  • Aposense Ltd. - Pipeline Products by Mechanism of Action, 2015

List of Figures

  • Aposense Ltd. - Pipeline by Top 10 Indication, 2015
  • Aposense Ltd. - Pipeline by Top 10 Target, 2015
  • Aposense Ltd. - Pipeline by Top 10 Route of Administration, 2015
  • Aposense Ltd. - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top